An in-mouth wafer to treat oral cancer– Biotech’s future

submitted by: nsf

To treat oral cancer, NSF-funded small business Privo Technologies has created a platform that delivers treatments directly to the affected area. Privo develops new classes of targeted treatments, such as chemotherapy drugs, designed to be delivered through the mouth’s mucous membranes. Privo founder Manijeh Goldberg talked about her company’s research at the 2014 BIO International Convention.

Cognitive Heart Failure explained via 3D Animation

submitted by: Scientific Animations

CHF or Congestive Heart Failure, a condition on continuos rise explained - Are lifestyle changes responsible for increase in cases of CHF? What are the main causes? Economic impact on health system? Innovations in diagnosing and treating CHF?
Medical Industry Trends for CHF

Microbial signature profiles of periodontally healthy and diseased patients

submitted by: apcolombo
Aim: To determine microbial profiles that discriminate periodontal health from different forms of periodontal diseases. Methods: Subgingival biofilm was obtained from patients with periodontal health (27), gingivitis (11), chronic periodontitis (35) and aggressive periodontitis (24), and analysed for the presence of >250 species/phylotypes using HOMIM. Microbial differences among groups were examined by Mann–Whitney U-test. Regression analyses were performed to determine microbial...
Authors: Talita Lourenço, Debora Heller, Carina Silva-Boghossian, Sean Cotton, Bruce Paster, Ana Paula Colombo

Breakthrough Therapies for Idiopathic Pulmonary Fibrosis

submitted by: mcgheek

Timothy P.M. Whelan, M.D., Medical Director of the Lung Transplant Program at the Medical University of South Carolina, discusses promising clinical trial results of new agents (pirfenidone, nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). To date, only supportive care and transplant (for eligible patients) have been available to IPF patients, but these new trial results could lead to FDA approval of the first drugs for IPF.

MyD88 knockout mice develop initial enlarged periapical

AIM: To characterize the formation and progression of experimentally induced periapical lesions in teeth of MyD88 knockout (MyD88 KO) mice compared with wild-type (WT) mice. METHODOLOGY: Periapical lesions were induced in the mandibular first molars of 30 WT and 30 MyD88 KO mice. After 7, 21 and 42 days, the animals were euthanized and the mandibles were subjected to histotechnical processing. Histological sections were stained with haematoxylin and eosin (HE), TRAP histoenzymology,...
Authors: Raquel Assed Bezerra da Silva, Paulo Nelson-Filho, Marília Pacífico Lucisano, Andiara De Rossi, Alexandra Mussolino de Queiroz, Lea Assed Bezerra da Silva

Helping health care technologies communicate

submitted by: nsf
Julian Goldman, a physician at Mass General Hospital, knows better than most the frustrations that doctors face when they're confronted with computer systems and devices that just won't communicate with each other. His lab has been a pioneer in developing open source tools and standards designed to integrate the various technologies used in homes and hospitals. The effort, in turn, led to the development of a community of likeminded researchers and manufacturers that would like to break...